Title |
New treatments for allergen immunotherapy
|
---|---|
Published in |
World Allergy Organization Journal, September 2014
|
DOI | 10.1186/1939-4551-7-23 |
Pubmed ID | |
Authors |
Mübeccel Akdis |
Abstract |
Allergen-specific immunotherapy (SIT) represents the only curative and specific way for the treatment of allergic diseases, which have reached a pandemic dimension in industrial countries affecting up to 20-30% of the population. Although applied for 100 years to cure allergy, SIT still faces several problems related to side effects and limited efficacy. Currently, allergen-SIT is performed with vaccines based on allergen extracts that can cause severe, often life threatening, anaphylactic reactions as well as new IgE sensitization to other allergens present in the extract. Low patient adherence and high costs due to long duration (3 to 5 years) of treatment have been commonly reported. Several strategies have been developed to tackle these issues and it became possible to produce recombinant allergen-SIT vaccines with reduced allergenic activity. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Argentina | 1 | 13% |
Romania | 1 | 13% |
Ecuador | 1 | 13% |
Spain | 1 | 13% |
Unknown | 4 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 4 | 50% |
Scientists | 2 | 25% |
Practitioners (doctors, other healthcare professionals) | 2 | 25% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 2% |
Unknown | 49 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 10 | 20% |
Student > Bachelor | 7 | 14% |
Researcher | 7 | 14% |
Other | 6 | 12% |
Student > Doctoral Student | 5 | 10% |
Other | 8 | 16% |
Unknown | 7 | 14% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 14 | 28% |
Agricultural and Biological Sciences | 13 | 26% |
Immunology and Microbiology | 10 | 20% |
Chemistry | 3 | 6% |
Social Sciences | 2 | 4% |
Other | 0 | 0% |
Unknown | 8 | 16% |